DK3728271T3 - Makrocykliske forbindelser til behandling af sygdomme - Google Patents
Makrocykliske forbindelser til behandling af sygdomme Download PDFInfo
- Publication number
- DK3728271T3 DK3728271T3 DK18893293.3T DK18893293T DK3728271T3 DK 3728271 T3 DK3728271 T3 DK 3728271T3 DK 18893293 T DK18893293 T DK 18893293T DK 3728271 T3 DK3728271 T3 DK 3728271T3
- Authority
- DK
- Denmark
- Prior art keywords
- diseases
- treatment
- macrocyclic compounds
- macrocyclic
- compounds
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 150000002678 macrocyclic compounds Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762607528P | 2017-12-19 | 2017-12-19 | |
| US201862727124P | 2018-09-05 | 2018-09-05 | |
| US201862779283P | 2018-12-13 | 2018-12-13 | |
| PCT/US2018/066158 WO2019126121A1 (en) | 2017-12-19 | 2018-12-18 | Macrocyclic compounds for treating disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3728271T3 true DK3728271T3 (da) | 2022-12-19 |
Family
ID=66992951
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK18893293.3T DK3728271T3 (da) | 2017-12-19 | 2018-12-18 | Makrocykliske forbindelser til behandling af sygdomme |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US10745416B2 (da) |
| EP (2) | EP3728271B1 (da) |
| JP (2) | JP7194188B2 (da) |
| KR (1) | KR20200101358A (da) |
| CN (1) | CN111511746B (da) |
| AU (1) | AU2018392332B2 (da) |
| BR (1) | BR112020012319A2 (da) |
| CA (1) | CA3083674A1 (da) |
| CL (1) | CL2020001632A1 (da) |
| DK (1) | DK3728271T3 (da) |
| EC (1) | ECSP20033467A (da) |
| ES (1) | ES2929467T3 (da) |
| HR (1) | HRP20221502T1 (da) |
| HU (1) | HUE060711T2 (da) |
| IL (1) | IL275265B2 (da) |
| JO (1) | JOP20200152A1 (da) |
| LT (1) | LT3728271T (da) |
| MX (1) | MX2020006490A (da) |
| PH (1) | PH12020550901A1 (da) |
| PL (1) | PL3728271T3 (da) |
| PT (1) | PT3728271T (da) |
| RS (1) | RS63787B1 (da) |
| SG (1) | SG11202005590PA (da) |
| SI (1) | SI3728271T1 (da) |
| TW (1) | TW201930312A (da) |
| WO (1) | WO2019126121A1 (da) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE064659T2 (hu) | 2015-11-02 | 2024-04-28 | Blueprint Medicines Corp | RET inhibitorai |
| HUE056615T2 (hu) | 2017-10-18 | 2022-02-28 | Incyte Corp | Tercier hidroxicsoportokkal szubsztituált kondenzált imidazol-származékok mint PI3K-gamma inhibitorok |
| ES2929467T3 (es) | 2017-12-19 | 2022-11-29 | Turning Point Therapeutics Inc | Compuestos macrocíclicos para tratar enfermedades |
| PT3710438T (pt) | 2017-12-19 | 2021-11-22 | Bristol Myers Squibb Co | Ácidos carbamoil ciclohexílicos n-ligados a triazol como antagonistas de lpa |
| BR112020020273A2 (pt) | 2018-04-03 | 2021-04-06 | Blueprint Medicines Corporation | Inibidor de ret para uso no tratamento de câncer tendo uma alteração de ret |
| JP7490635B2 (ja) | 2018-08-10 | 2024-05-27 | ブループリント メディシンズ コーポレイション | Ｅｇｆｒ変異がんの処置 |
| MX2021004538A (es) | 2018-10-22 | 2021-09-10 | Esker Therapeutics Inc | Inhibidores de tyk2 y sus usos. |
| WO2020257189A1 (en) * | 2019-06-19 | 2020-12-24 | Turning Point Therapeutics, Inc. | Macrocycles for treating disease |
| WO2020257165A1 (en) * | 2019-06-19 | 2020-12-24 | Turning Point Therapeutics, Inc. | Macrocycles for use in treating disease |
| PE20220135A1 (es) * | 2019-06-19 | 2022-01-27 | Turning Point Therapeutics Inc | Polimorfos de un inhibidor de cinasas macrociclicas |
| WO2021027503A1 (zh) * | 2019-08-12 | 2021-02-18 | 罗欣药业(上海)有限公司 | 三环类化合物、其制备方法、中间体及应用 |
| KR20220133869A (ko) * | 2019-12-03 | 2022-10-05 | 터닝 포인트 테라퓨틱스, 인크. | 질환 치료에 사용하기 위한 거대고리 |
| WO2021244609A1 (zh) | 2020-06-04 | 2021-12-09 | 成都倍特药业股份有限公司 | 具有大环结构的化合物及其用途 |
| WO2023060022A1 (en) * | 2021-10-05 | 2023-04-13 | Turning Point Therapeutics, Inc. | Synthesis of macrocyclic compounds |
| WO2024017380A1 (zh) * | 2022-07-22 | 2024-01-25 | 南京明德新药研发有限公司 | 含三并环的大环类化合物及其应用 |
| WO2024040131A1 (en) * | 2022-08-17 | 2024-02-22 | Treeline Biosciences, Inc. | Pyridopyrimidine kras inhibitors |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0690843T3 (da) * | 1993-03-25 | 2000-11-13 | Upjohn Co | Fornyl- eller cyanosubstituerede indolderivater med dopaninerg aktivitet |
| IL111850A (en) | 1993-12-07 | 2002-11-10 | Lilly Co Eli | 3, 4 - Bite (indolyl) from cyclic amides that inhibit kinase C protein, their preparation and boils that contain |
| RS49779B (sr) | 1998-01-12 | 2008-06-05 | Glaxo Group Limited, | Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze |
| ES2245994T3 (es) | 2000-12-08 | 2006-02-01 | Ortho-Mcneil Pharmaceutical, Inc. | Compuestos macro-heterociclicos utilizados como inhibidores de quinasa. |
| AU2009288021B2 (en) | 2008-09-08 | 2015-06-18 | Merck Patent Gmbh | Macrocyclics pyrimidines as Aurora kinase inhibitors |
| SI2350075T1 (sl) | 2008-09-22 | 2014-06-30 | Array Biopharma, Inc. | Substituirane imidazo (1,2b)piridazinske spojine kot Trk kinazni inhibitorji |
| ES2588504T3 (es) | 2008-10-22 | 2016-11-03 | Array Biopharma, Inc. | Compuestos de pirazolo[1,5-a]pirimidina sustituidos como compuestos intermedios en la síntesis de inhibidores de TRK quinasa |
| EP2348860B1 (en) | 2008-10-31 | 2015-05-27 | Genentech, Inc. | Pyrazolopyrimidine jak inhibitor compounds and methods |
| EP2488521B1 (en) | 2009-10-13 | 2013-12-18 | Elanco Animal Health Ireland Limited | Macrocyclic integrase inhibitors |
| SA111320200B1 (ar) | 2010-02-17 | 2014-02-16 | ديبيوفارم اس ايه | مركبات ثنائية الحلقة واستخداماتها كمثبطات c-src/jak مزدوجة |
| SG10201506591TA (en) * | 2010-05-20 | 2015-09-29 | Array Biopharma Inc | Macrocyclic compounds as trk kinase inhibitors |
| US8637516B2 (en) | 2010-09-09 | 2014-01-28 | Irm Llc | Compounds and compositions as TRK inhibitors |
| EP2508607A1 (en) | 2011-04-07 | 2012-10-10 | Helmholtz-Zentrum für Infektionsforschung GmbH | Medicament for liver regeneration and for treatment of liver failure |
| WO2013001310A1 (en) | 2011-06-30 | 2013-01-03 | Centro Nacional De Investigaciones Oncológicas (Cnio) | Macrocyclic compounds and their use as cdk8 inhibitors |
| KR20140059236A (ko) | 2011-08-19 | 2014-05-15 | 머크 샤프 앤드 돔 코포레이션 | Hcv 프로테아제 억제제의 결정 형태 |
| HUE027318T2 (en) | 2011-09-30 | 2016-10-28 | Oncodesign Sa | Macrocyclic FLT3 kinase inhibitors |
| MX350844B (es) | 2012-03-06 | 2017-09-22 | Pfizer | Derivados macrocíclicos para el tratamiento de enfermedades proliferativas. |
| JP6418949B2 (ja) | 2012-03-09 | 2018-11-07 | レクシコン ファーマシューティカルズ インコーポレイテッド | イミダゾ［１，２−ｂ］ピリダジン系化合物、それを含む組成物、及びそれらを使用する方法 |
| DK2834243T3 (da) | 2012-03-09 | 2018-07-23 | Lexicon Pharmaceuticals Inc | Pyrazol[1,5-a]pyrimidin-baserede forbindelser, sammensætninger omfattende disse og fremgangsmåder til disses anvendelse |
| GB201205669D0 (en) | 2012-03-30 | 2012-05-16 | Agency Science Tech & Res | Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof |
| UA121206C2 (uk) | 2014-01-24 | 2020-04-27 | Турнінґ Поінт Терапьютикс, Інк. | Діарильні макроцикли як модулятори протеїнкіназ |
| DK3172213T3 (da) * | 2014-07-21 | 2021-12-13 | Dana Farber Cancer Inst Inc | Makrocykliske kinasehæmmere og anvendelser deraf |
| ES2864839T3 (es) | 2015-07-02 | 2021-10-14 | Turning Point Therapeutics Inc | Macrociclos de diarilo quirales como moduladores de proteína quinasas |
| JP6917974B2 (ja) | 2015-07-06 | 2021-08-11 | ターニング・ポイント・セラピューティクス・インコーポレイテッドＴｕｒｎｉｎｇ Ｐｏｉｎｔ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | ジアリール大環状多形 |
| EP3733187A1 (en) | 2015-07-21 | 2020-11-04 | Turning Point Therapeutics, Inc. | Chiral diaryl macrocycle and use thereof in the treatment of cancer |
| CN112920201A (zh) * | 2016-03-03 | 2021-06-08 | 深圳市塔吉瑞生物医药有限公司 | 一种大环化合物及包含该化合物的组合物 |
| CN106008531B (zh) * | 2016-05-30 | 2019-01-11 | 上海交通大学 | 多环稠合大环内酰胺类化合物的抗胰腺癌用途 |
| RU2019105587A (ru) | 2016-07-28 | 2020-08-28 | Тёрнинг Поинт Терапьютикс, Инк. | Макроциклические ингибиторы киназ |
| TWI808958B (zh) | 2017-01-25 | 2023-07-21 | 美商特普醫葯公司 | 涉及二芳基巨環化合物之組合療法 |
| UA126158C2 (uk) | 2017-07-28 | 2022-08-25 | Тьорнінґ Поінт Терапьютикс, Інк. | Макроциклічні сполуки і їх використання |
| HUE056615T2 (hu) | 2017-10-18 | 2022-02-28 | Incyte Corp | Tercier hidroxicsoportokkal szubsztituált kondenzált imidazol-származékok mint PI3K-gamma inhibitorok |
| PT3710438T (pt) | 2017-12-19 | 2021-11-22 | Bristol Myers Squibb Co | Ácidos carbamoil ciclohexílicos n-ligados a triazol como antagonistas de lpa |
| ES2929467T3 (es) | 2017-12-19 | 2022-11-29 | Turning Point Therapeutics Inc | Compuestos macrocíclicos para tratar enfermedades |
| GB201721235D0 (en) | 2017-12-19 | 2018-01-31 | Syngenta Participations Ag | Polymorphs |
| WO2019126122A1 (en) * | 2017-12-19 | 2019-06-27 | Tp Therapeutics, Inc. | Macrocyclic kinase inhibitors and their use |
| WO2019120267A1 (zh) | 2017-12-22 | 2019-06-27 | 成都先导药物开发股份有限公司 | 一种咪唑并[1,2-b]哒嗪大环类激酶抑制剂 |
| CA3099493C (en) | 2018-04-18 | 2023-08-22 | Hitgen Inc. | Macrocyclic kinase inhibitor |
-
2018
- 2018-12-18 ES ES18893293T patent/ES2929467T3/es active Active
- 2018-12-18 AU AU2018392332A patent/AU2018392332B2/en active Active
- 2018-12-18 JP JP2020533594A patent/JP7194188B2/ja active Active
- 2018-12-18 CA CA3083674A patent/CA3083674A1/en active Pending
- 2018-12-18 PL PL18893293.3T patent/PL3728271T3/pl unknown
- 2018-12-18 LT LTEPPCT/US2018/066158T patent/LT3728271T/lt unknown
- 2018-12-18 DK DK18893293.3T patent/DK3728271T3/da active
- 2018-12-18 WO PCT/US2018/066158 patent/WO2019126121A1/en unknown
- 2018-12-18 HR HRP20221502TT patent/HRP20221502T1/hr unknown
- 2018-12-18 KR KR1020207017739A patent/KR20200101358A/ko not_active Application Discontinuation
- 2018-12-18 MX MX2020006490A patent/MX2020006490A/es unknown
- 2018-12-18 PT PT188932933T patent/PT3728271T/pt unknown
- 2018-12-18 BR BR112020012319-6A patent/BR112020012319A2/pt unknown
- 2018-12-18 SG SG11202005590PA patent/SG11202005590PA/en unknown
- 2018-12-18 CN CN201880082563.6A patent/CN111511746B/zh active Active
- 2018-12-18 JO JOP/2020/0152A patent/JOP20200152A1/ar unknown
- 2018-12-18 RS RS20221099A patent/RS63787B1/sr unknown
- 2018-12-18 EP EP18893293.3A patent/EP3728271B1/en active Active
- 2018-12-18 HU HUE18893293A patent/HUE060711T2/hu unknown
- 2018-12-18 EP EP22191652.1A patent/EP4151641A1/en active Pending
- 2018-12-18 SI SI201830779T patent/SI3728271T1/sl unknown
- 2018-12-19 TW TW107145927A patent/TW201930312A/zh unknown
-
2020
- 2020-01-30 US US16/777,717 patent/US10745416B2/en active Active
- 2020-05-05 US US16/866,983 patent/US11286265B2/en active Active
- 2020-06-10 IL IL275265A patent/IL275265B2/en unknown
- 2020-06-15 PH PH12020550901A patent/PH12020550901A1/en unknown
- 2020-06-17 CL CL2020001632A patent/CL2020001632A1/es unknown
- 2020-06-19 EC ECSENADI202033467A patent/ECSP20033467A/es unknown
-
2022
- 2022-02-14 US US17/670,665 patent/US20220306652A1/en active Pending
- 2022-12-09 JP JP2022197141A patent/JP2023027237A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3728271T3 (da) | Makrocykliske forbindelser til behandling af sygdomme | |
| DK3570844T3 (da) | Azolopyrimidin til behandlingen af kræftrelaterede lidelser | |
| DK3245206T3 (da) | Pyrazinforbindelser til behandling af infektionssygdomme | |
| DK3431105T3 (da) | Medicinsk sammensætning til behandling af cancer | |
| DK3326641T3 (da) | Rna-holdig sammensætning til behandling af tumorsygdomme | |
| DK3347030T3 (da) | Brug af pasteuriseret akkermansia til behandling af stofskiftesygdomme | |
| DK3212233T3 (da) | Kombinationsterapi til behandling af sygdom | |
| DK3439635T3 (da) | Formuleringer til behandling af fast tumor | |
| DK3143025T3 (da) | Forbindelser til behandling af spinal muskelatrofi | |
| DK3240612T3 (da) | Fremgangsmåder til behandling af nethindesygdomme | |
| DK3362066T3 (da) | Kombinationsterapi til behandling af maligniteter | |
| DK3390390T3 (da) | Bipyrazolylderivater egnede til behandling af autoimmunsygdomme | |
| DK3148529T3 (da) | Forbindelser til behandling af hjernecancer | |
| DK3785733T3 (da) | Farmaceutisk sammensætning til behandling af autisme | |
| DK3609529T3 (da) | Rna til behandling af autoimmune sygdomme | |
| DK3169328T3 (da) | Quinolinderivater til behandling af inflammationssygdomme | |
| DK3498278T3 (da) | Forbindelser til behandling af sygdomme relateret til DUX4-ekspression | |
| DK3436074T3 (da) | Thiazolidforbindelser til behandling af virale infektioner | |
| DK3430143T3 (da) | Inhibitorer af SRSF1 til behandlingen af neurodegenerative sygdomme | |
| DK3400072T3 (da) | Formuleringer til behandling af blærecancer | |
| DK3468604T3 (da) | Farmaceutiske kombinationer til behandling af cancer | |
| DK3548061T3 (da) | Behandling af neurologiske sygdomme | |
| DK3578562T3 (da) | L-valinatamidbenzoxaborolderivater til behandling af parasitiske sygdomme | |
| DK3097085T3 (da) | Benzoxazinonderivater til behandling af hudsygdomme | |
| DK3210973T3 (da) | Heteroarylforbindelser til behandling af oftalmiske sygdomme |